Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("RICHARDSON, Paul G")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 144

  • Page / 6
Export

Selection :

  • and

Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray AreaBIANCHI, Giada; RICHARDSON, Paul G; ANDERSON, Kenneth C et al.Journal of clinical oncology. 2014, Vol 32, Num 20, pp 2125-2132, issn 0732-183X, 8 p.Article

Treatment Options for Relapsed and Refractory Multiple Myeloma : Multiple MyelomaLONIAL, Sagar; MITSIADES, Constantine S; RICHARDSON, Paul G et al.Clinical cancer research (Print). 2011, Vol 17, Num 6, pp 1264-1277, issn 1078-0432, 14 p.Article

Toward Better Therapy for Lymphoma and MyelomaFISHER, Richard I; RICHARDSON, Paul G.Journal of clinical oncology. 2011, Vol 29, Num 14, issn 0732-183X, 139 p.Serial Issue

A man with a large tumor of the skullRICHARDSON, Paul G; KASSARJIAN, Ara; WEN JING et al.The New England journal of medicine. 2004, Vol 351, Num 25, pp 2637-2645, issn 0028-4793, 9 p.Article

Role of Functional Imaging in the Management of LymphomaCHESON, Bruce D.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1844-1854, issn 0732-183X, 11 p.Article

Lenalidomide in multiple myelomaRICHARDSON, Paul G; MITSIADES, Constantine; HIDESHIMA, Teru et al.Expert review of anticancer therapy. 2006, Vol 6, Num 8, pp 1165-1173, issn 1473-7140, 9 p.Article

The Gray Zone Between Burkitt's Lymphoma and Diffuse Large B-Cell Lymphoma From a Genetics PerspectiveSALAVERRIA, Itziar; SIEBERT, Reiner.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1835-1843, issn 0732-183X, 9 p.Article

Allogeneic Transplantation for LymphomaCHAKRAVERTY, Ronjon; MACKINNON, Stephen.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1855-1863, issn 0732-183X, 9 p.Article

Transformation of Indolent B-Cell LymphomasMONTOTO, Silvia; FITZGIBBON, Jude.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1827-1834, issn 0732-183X, 8 p.Article

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myelomaYASUI, Hiroshi; HIDESHIMA, Teru; RICHARDSON, Paul G et al.British journal of haematology. 2006, Vol 132, Num 4, pp 385-397, issn 0007-1048, 13 p.Article

Proteasome inhibition in hematologic malignancies : Proteasome inhibitionRICHARDSON, Paul G; HIDESHIMA, Teru; MITSIADES, Constantine et al.Annals of medicine (Helsinki). 2004, Vol 36, Num 4, pp 304-314, issn 0785-3890, 11 p.Article

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple MyelomaJAKUBOWIAK, Andrzej J; BENSON, Don M; BENSINGER, William et al.Journal of clinical oncology. 2012, Vol 30, Num 16, pp 1960-1965, issn 0732-183X, 6 p.Article

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialJAKUBOWIAK, Andrzej J; GRIFFITH, Kent A; ANDERSON, Tara et al.Blood. 2011, Vol 118, Num 3, pp 535-543, issn 0006-4971, 9 p.Article

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II TrialRICHARDSON, Paul G; WOLF, Jeff; MARTIN, Tom et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4243-4249, issn 0732-183X, 7 p.Article

Monoclonal antibodies in the treatment of multiple myelomaRICHARDSON, Paul G; LONIAL, Sagar; JAKUBOWIAK, Andrzej J et al.British journal of haematology. 2011, Vol 154, Num 6, pp 745-754, issn 0007-1048, 10 p.Article

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrôm MacroglobulinemiaGHOBRIAL, Irene M; WANLING XIE; HARRIS, Brianna et al.American journal of hematology. 2010, Vol 85, Num 9, pp 670-674, issn 0361-8609, 5 p.Article

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235MCMILLIN, Douglas W; OOI, Melissa; MUNSHI, Nikhil C et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 14, pp 5835-5842, issn 0008-5472, 8 p.Article

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensKUMAR, Shaji; GIRALT, Sergio; SAN MIGUEL, Jesus et al.Blood. 2009, Vol 114, Num 9, pp 1729-1735, issn 0006-4971, 7 p.Article

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure : a multicenter retrospective studyCHANAN-KHAN, Asher A; KAUFMAN, Jonathan L; MEHTA, Jayesh et al.Blood. 2007, Vol 109, Num 6, pp 2604-2606, issn 0006-4971, 3 p.Article

Antimyeloma activity of heat shock protein-90 inhibitionCHANAN-KBAN, Asher; MITSIADES, Constantine S; MUNSHI, Nikhil C et al.Blood. 2006, Vol 107, Num 3, issn 0006-4971, 850,1092-1100 [10 p.]Article

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma : Final time-to-event results from the SUMMIT trialRICHARDSON, Paul G; BARLOGIE, Bart; BERENSON, James et al.Cancer. 2006, Vol 106, Num 6, pp 1316-1319, issn 0008-543X, 4 p.Article

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoHAMASAKI, Makoto; HIDESHIMA, Teru; JACOB, Gary S et al.Blood. 2005, Vol 105, Num 11, pp 4470-4476, issn 0006-4971, 7 p.Article

Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal functionJAGANNATH, Sundar; BARLOGIE, Bart; ESSELTINE, Dixie L et al.Cancer. 2005, Vol 103, Num 6, pp 1195-1200, issn 0008-543X, 6 p.Article

Bortezomib or high-dose dexamethasone for relapsed multiple myelomaRICHARDSON, Paul G; SONNEVELD, Pieter; REECE, Donna et al.The New England journal of medicine. 2005, Vol 352, Num 24, pp 2487-2498, issn 0028-4793, 12 p.Article

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsMITSIADES, Nicholas; MITSIADES, Constantine S; LIBERMANN, Towia A et al.Blood. 2003, Vol 101, Num 6, pp 2377-2380, issn 0006-4971, 4 p.Article

  • Page / 6